We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Smart Tear Sensors May Help Detect Shifts in Eye Health Over Time

By HospiMedica International staff writers
Posted on 14 Oct 2026

Dry eye disease, glaucoma, and other ocular disorders are often monitored through intermittent office visits. More...

This approach can miss day-to-day changes in symptoms and tear-film behavior. Tears contain chemical signals linked to ocular health and, in some cases, broader physiological status. Researchers have now outlined a framework for wearable tear-based sensors that could support more reliable long-term eye health monitoring.

The Terasaki Institute for Biomedical Innovation, with collaborators at UC San Diego and USC, has described design priorities for next-generation ocular sensors in a Nature Sensors perspective. The proposed approach focuses on the tear film as a dynamic biological interface, rather than treating tears only as a source of biomarkers. It emphasizes that blinking, evaporation, and fluid turnover can affect sensor readings during real-world wear.

The framework calls for matching each biological signal to an appropriate sensing frequency and device format. Signals such as pH and electrolytes may require different monitoring strategies than larger proteins or inflammatory markers. The authors also recommend combining chemical sensing with contextual data, including blink patterns and tear flow, to help distinguish true biological changes from normal tear-film fluctuations.

The perspective identifies four areas needed for clinical translation. These include the biological interface, device performance during routine wear, clinical validation, and user trust. It also describes smart contact lenses, punctal devices, and periocular patches as complementary formats for different monitoring needs.

Dry eye disease is identified as a natural first proving ground because it is closely tied to tear-film instability and symptom fluctuation. The authors also highlight glaucoma monitoring and metabolic tracking as possible applications. They note that progress will require longitudinal studies that compare tear-based measurements with established clinical measures.

“Tear film isn’t just a source of biomarkers; it’s a constantly moving physiological system. If a sensor doesn’t account for blinking, evaporation, and fluid turnover, it’s very easy to mistake normal tear-film behavior for a biological signal,” said Dr. Chia-Wei Liu, Postdoctoral Researcher at the Terasaki Institute for Biomedical Innovation.

“Our goal is to move the field past counting how many biomarkers a device can detect and toward asking whether the readings can actually be trusted over time. That means designing sensors and interpretation methods together, not as separate problems,” said Dr. Yangzhi Zhu, Principal Investigator and Assistant Professor at the Terasaki Institute.

Related Links
Terasaki Institute for Biomedical Innovation


Gold Member
12-Channel ECG
CM1200B
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Vessel Sealing Instrument
ERGOseal
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.